Nektar Therapeutics (NASDAQ:NKTR) went up by 8.45% from its latest closing price compared to the recent 1-year high of $26.75. The company’s stock price has collected 10.96% of gains in the last five trading sessions. Press Release reported 13 hours ago that Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study
Is It Worth Investing in Nektar Therapeutics (NASDAQ :NKTR) Right Now?
Plus, the 36-month beta value for NKTR is at 1.42. Opinions of the stock are interesting as 5 analysts out of 14 who provided ratings for Nektar Therapeutics declared the stock was a “buy,” while 1 rated the stock as “overweight,” 8 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $24.91. NKTR currently public float of 182.23M and currently shorts hold a 9.52% ratio of that float. Today, the average trading volume of NKTR was 843.43K shares.
NKTR’s Market Performance
NKTR stocks went up by 10.96% for the week, with a monthly jump of 30.20% and a quarterly performance of 6.30%, while its annual performance rate touched -8.71%. The volatility ratio for the week stands at 4.06% while the volatility levels for the past 30 days are set at 3.83% for Nektar Therapeutics. The simple moving average for the period of the last 20 days is 13.79% for NKTR stocks with a simple moving average of -3.31% for the last 200 days.
Analysts’ Opinion of NKTR
Many brokerage firms have already submitted their reports for NKTR stocks, with BofA Securities repeating the rating for NKTR by listing it as a “Neutral.” The predicted price for NKTR in the upcoming period, according to BofA Securities is $18 based on the research report published on September 10th of the current year 2021.
Stifel, on the other hand, stated in their research note that they expect to see NKTR reach a price target of $24, previously predicting the price at $22. The rating they have provided for NKTR stocks is “Buy” according to the report published on June 28th, 2021.
Goldman gave a rating of “Neutral” to NKTR, setting the target price at $24 in the report published on May 18th of the current year.
NKTR Trading at 13.88% from the 50-Day Moving Average
After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.76% of loss for the given period.
Volatility was left at 3.83%, however, over the last 30 days, the volatility rate increased by 4.06%, as shares surge +26.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.84% upper at present.
During the last 5 trading sessions, NKTR rose by +10.96%, which changed the moving average for the period of 200-days by +3.81% in comparison to the 20-day moving average, which settled at $15.76. In addition, Nektar Therapeutics saw 4.24% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at NKTR starting from CHESS ROBERT, who sale 10,279 shares at the price of $16.02 back on Sep 09. After this action, CHESS ROBERT now owns 274,273 shares of Nektar Therapeutics, valued at $164,670 using the latest closing price.
CHESS ROBERT, the Director of Nektar Therapeutics, sale 8,000 shares at $16.00 during a trade that took place back on Sep 08, which means that CHESS ROBERT is holding 274,273 shares at $128,000 based on the most recent closing price.
Stock Fundamentals for NKTR
Current profitability levels for the company are sitting at:
- -248.45 for the present operating margin
- +81.21 for the gross margin
The net margin for Nektar Therapeutics stands at -290.65. The total capital return value is set at -23.35, while invested capital returns managed to touch -29.84. Equity return is now at value -45.70, with -32.30 for asset returns.
Based on Nektar Therapeutics (NKTR), the company’s capital structure generated 29.74 points at debt to equity in total, while total debt to capital is 22.92. Total debt to assets is 20.82, with long-term debt to equity ratio resting at 28.45. Finally, the long-term debt to capital ratio is 21.93.
When we switch over and look at the enterprise to sales, we see a ratio of 15.00, with the company’s debt to enterprise value settled at 0.14. The receivables turnover for the company is 3.79 and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.83.